Synergistic RU486 and olaparib therapy enhances apoptosis in endometriosis by simultaneously targeting hormonal signalling and DNA repair
British Journal of Pharmacology · 2026-06 · 183 (11) · 2947-2968
DOI: 10.1111/bph.70360 ↗Kurz gefasst
Fachartikel in der Zeitschrift British Journal of Pharmacology, online erschienen am 18.02.2026. Verfasst von Yujie Peng und 10 weiteren Autor:innen. Beteiligte Einrichtung: Research Center for Clinical Pharmacy, College of Pharmaceutical Sciences, Zhejiang University, Hangzhou, China. Hauptthemen laut MEDLINE: Piperazines, Endometriosis, Apoptosis, Phthalazines. Die Arbeit nennt 85 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Natural Science Foundation of China, Natural Science Foundation of Zhejiang Province, Zhejiang Pharmaceutical Association Hospital Pharmacy Scientific Research Program.
Abstract (Originalsprache)
Background and Purpose Endometriosis is a chronic, hormone‐dependent disorder characterized by ectopic implantation of endometrial tissue, often accompanied by pain and infertility. Although the progesterone receptor modulator RU486 is effective for pain relief, its impact on lesion regression is limited, possibly due to apoptosis resistance and overexpression of PARP1 in endometriotic cells. This study aimed to evaluate the synergistic therapeutic efficacy of combining RU486 with the PARP inhibitor olaparib, focusing on reactivating p53‐dependent apoptosis in endometriotic lesions. Experimental Approach Primary ectopic endometrial stromal cells (EESCs) were used to assess the effects of RU486 and olaparib on cytotoxicity, apoptosis, DNA damage, mitochondrial membrane potential, and cell migration. Mechanistic investigations included flow cytometry, western blotting, RT‐qPCR, immunofluorescence, and comet assays. A murine endometriosis model was established to evaluate in vivo lesion suppression, pain behaviour, hormone levels, and treatment safety following combination therapy. Key Results RU486 and olaparib exhibited strong synergy at a 1:4 ratio, significantly enhancing apoptosis in EESCs by coactivating p53 through distinct mechanisms—transcriptional up‐regulation by RU486 and posttranslational stabilization by olaparib. This synergy intensified Bax/Bcl‐2‐mediated mitochondrial dysfunction, caspase‐3 activation, and PARP1 cleavage. In vivo, the combination therapy achieved a 77.5% lesion weight regression, significantly exceeding monotherapies, while maintaining robust analgesic effects. Histological and molecular analyses confirmed DNA damage and enhanced apoptosis in lesions. Conclusion and Implications The combination medication enhanced apoptotic sensitivity in endometriosis by restoring p53 activity through targeting hormonal signalling and DNA repair pathways. This strategy offered strong potential for clinical translation.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Research Center for Clinical Pharmacy, College of Pharmaceutical Sciences, Zhejiang University, Hangzhou, China.
- Women's Hospital, Zhejiang University School of Medicine, Hangzhou, China.
ORCID-Profile: Huidi Jiang
Förderung
- National Natural Science Foundation of China
- Natural Science Foundation of Zhejiang Province
- Zhejiang Pharmaceutical Association Hospital Pharmacy Scientific Research Program
Zitieren
APA
Peng, Y., Zhang, M., Zhu, L., Qian, W., Yan, J., Jiang, H., Xin, Y., Zhang, Y., Sun, D., Fei, W., & Zhao, M. (2026). Synergistic RU486 and olaparib therapy enhances apoptosis in endometriosis by simultaneously targeting hormonal signalling and DNA repair. British Journal of Pharmacology, 183(11), 2947-2968. https://doi.org/10.1111/bph.70360
Vancouver
Peng Y, Zhang M, Zhu L, Qian W, Yan J, Jiang H, et al. Synergistic RU486 and olaparib therapy enhances apoptosis in endometriosis by simultaneously targeting hormonal signalling and DNA repair. British Journal of Pharmacology. 2026;183(11):2947-2968. doi:10.1111/bph.70360
BibTeX
@article{Peng2026,
author = {Peng, Yujie and Zhang, Meng and Zhu, Libo and Qian, Wenqiang and Yan, Jingjing and Jiang, Huidi and Xin, Yu and Zhang, Ying and Sun, Dongli and Fei, Weidong and Zhao, Mengdan},
title = {Synergistic RU486 and olaparib therapy enhances apoptosis in endometriosis by simultaneously targeting hormonal signalling and DNA repair},
journal = {British Journal of Pharmacology},
year = {2026},
volume = {183},
number = {11},
pages = {2947--2968},
doi = {10.1111/bph.70360}
}
EUVIMED